Tirzepatide is the second of a new generation of drugs approved to treat Type 2 diabetes and obesity. The FDA approved Novo ...

The FDA recently approved Zepbound, a weekly injectable drug targeted to treat obesity. The medication contains tirzepatide, the same active ingredient that is also present in the diabetes drug ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Novo Nordisk is celebrating the FDA approval of its ... sales hopes for the drug. There's also some upside potential from ongoing trials of semaglutide in obesity-related heart failure with ...

The FDA has approved PureTech Health’s ‘space occupying ... whose products have emerged as the biggest selling anti-obesity drugs. In contrast, PureTech said Plenity is considered a medical ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

The U.S. Food and Drug Administration (FDA) approved the drug for weight control ... The drug has caused a lot of sensation as it attacks obesity. It was found that people on the drug ate less.

The FDA cleared a drug-free capsule for weight management in adults with a BMI of 25-40, said maker Epitomee Medical. Once ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...